JAGX

1.33

13.68% 0.16

Vorhandelsmarkt: 1.33

Jaguar Health Inc (JAGX)

Überblick Nachrichten Preisverlauf Financials Warum fällt JAGX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.17

Offen:

$1.18

24-Stunden-Volumen:

2.21M

Relative Volume:

10.95

Marktkapitalisierung:

$4.97M

Einnahmen:

$10.48M

Nettoeinkommen (Verlust:

$-37.74M

KGV:

-0.0822

EPS:

-16.1846

Netto-Cashflow:

$-29.03M

1W Leistung:

+30.39%

1M Leistung:

-20.83%

6M Leistung:

-65.27%

1J Leistung:

-94.63%

1-Tages-Spanne:

$1.05

$1.44

1-Wochen-Bereich:

$1.00

$1.44

52-Wochen-Spanne:

$1.00

$33.25

Jaguar Health Inc Stock (JAGX) Company Profile

Firmenname

Jaguar Health Inc

Sektor

Healthcare (1124)

Branche

Biotechnology (627)

Telefon

415-371-8300

Adresse

200 PINE STREET SUITE 400, SAN FRANCISCO, CA

Mitarbeiter

Twitter

@Jaguar_Health

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

JAGX's Discussions on Twitter

Vergleichen Sie JAGX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
JAGX Jaguar Health Inc	1.33	4.37M	10.48M	-37.74M	-29.03M	-16.18
VRTX Vertex Pharmaceuticals Inc	444.64	110.88B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	726.21	72.79B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	890.11	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	404.46	54.85B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	189.85	41.41B	447.02M	-1.18B	-906.14M	-6.1812

Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-07-07	Eingeleitet	Cantor Fitzgerald	Overweight
2017-07-11	Eingeleitet	Rodman & Renshaw	Buy

Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten

12:16 PM

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - USA Today

12:16 PM

Dec 10, 2025

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders - azcentral.com and The Arizona Republic

Dec 10, 2025

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones - The Florida Times-Union

Dec 10, 2025

FDA extends conditional approval for Jaguar Health’s canine drug By Investing.com - Investing.com Australia

Dec 10, 2025

Dec 09, 2025

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Daytona Beach News-Journal

Dec 09, 2025

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Bluffton Today

Dec 09, 2025

Dec 08, 2025

Jaguar Health Announces Promising Trial Results for Crofelemer - TipRanks

Dec 08, 2025

Jaguar Health (NASDAQ: JAGX) clears all special meeting items, notes MVID trial progress - Stock Titan

Dec 08, 2025

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue - Livingston Daily

Dec 08, 2025

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series - Leesburg Daily Commercial

Dec 08, 2025

Dec 06, 2025

Sakthi Sugars Limited (SAKHTISUG) vs yyyFibonacci Extensions & Free Gain Edge With Data - earlytimes.in

Dec 06, 2025

Dec 05, 2025

JAGX S-3/A及美國證券交易委員會申報文件 - Yahoo 財經

Dec 05, 2025

How dovish Fed policy supports Jaguar Health Inc. (1JA0) stockJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - Newser

Dec 05, 2025

Dec 04, 2025

Is Jaguar Health Inc. stock near bottom after declineWeekly Gains Summary & Weekly Sector Rotation Insights - Newser

Dec 04, 2025

Dec 03, 2025

Jaguar Health (JAGX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 03, 2025